Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Operating expenses:
Research and development	$ 37,189	$ 56,448
Research and development related success payments and contingent consideration	1,957	38,007
General and administrative	11,484	16,269
Total operating expenses	50,630	110,724
Loss from operations	(50,630)	(110,724)
Interest income, net	992	3,034
Other income, net	249	215
Net loss	$ (49,389)	$ (107,475)
Net loss per common share - basic	$ (0.21)	$ (0.49)
Net loss per common share - diluted	$ (0.21)	$ (0.49)
Weighted-average number of common shares - basic	237,578	217,290
Weighted-average number of common shares - diluted	237,578	217,290